Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Clinical Outcome
10 results:

  • 1. MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer.
    McCoy P; Mangiola S; Macintyre G; Hutchinson R; Tran B; Pope B; Georgeson P; Hong MKH; Kurganovs N; Lunke S; Clarkson MJ; Cmero M; Kerger M; Stuchbery R; Chow K; Haviv I; Ryan A; Costello AJ; Corcoran NM; Hovens CM
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1167-1180. PubMed ID: 34108644
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer.
    Lin PC; Yeh YM; Wu PY; Hsu KF; Chang JY; Shen MR
    Sci Rep; 2019 Mar; 9(1):3931. PubMed ID: 30850667
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.
    González I; Goyal B; Xia MD; Pai RK; Ma C
    Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. clinical Impact of Mismatch Repair Protein Testing on outcome of Early Staged colorectal Carcinomas.
    Gandhi JS; Goswami M; Sharma A; Tanwar P; Gupta G; Gupta N; Pasricha S; Mehta A; Singh S; Agarwal M; Gupta N
    J Gastrointest Cancer; 2018 Dec; 49(4):406-414. PubMed ID: 28585041
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
    Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
    Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Variations in mismatch repair genes and colorectal cancer risk and clinical outcome.
    Vymetalkova V; Pardini B; Rosa F; Di Gaetano C; Novotny J; Levy M; Buchler T; Slyskova J; Vodickova L; Naccarati A; Vodicka P
    Mutagenesis; 2014 Jul; 29(4):259-65. PubMed ID: 24755277
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.
    Zaanan A; Meunier K; Sangar F; Fléjou JF; Praz F
    Cell Oncol (Dordr); 2011 Jun; 34(3):155-76. PubMed ID: 21484480
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
    Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
    Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.